Alzheimer’s Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Alzheimer’s Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

  • September 2021 •
  • 140 pages •
  • Report ID: 6154334 •
  • Format: PDF
The global alzheimer’s drugs market reached a value of US$ 6.34 Billion in 2020. Looking forward, the analyst expects the market to grow at a CAGR of 6.50% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Alzheimer’s is a disease characterized by the degeneration of nerve cells in several areas of the brain. It causes loss of cognitive function, such as memory, language, thinking and behavior. The common symptoms of Alzheimer’s include depression, memory impairment, loss of inhibitions, and problems with thinking and reasoning. It is usually diagnosed by performing physical exams, blood tests, brain imaging, and mental status and neuropsychological testing. According to the results, doctors prescribe different medications to alleviate symptoms. Alzheimer’s drugs influence the functions of neurotransmitters, the chemicals involved in carrying messages between nerve cells in the brain.

Alzheimer’s Drugs Market Trends:
Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer’s disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth. Furthermore, the leading pharmaceutical companies are focusing on the development of drugs that prevent the disease and provide long-lasting improvements in cognitive functions. The market growth is further supported by the expansion of telehealth services and the growing traction of online pharmacies. These platforms have enabled disease diagnosis and drug delivery in remote regions. Apart from this, various Alzheimer’s drugs are presently under late-stage clinical trials, including Aducanumab, Solanezumab and Insulin. The development of these drugs is anticipated to propel the market growth in the coming years.

Key Market Segmentation:
the analyst provides an analysis of the key trends in each sub-segment of the global alzheimer’s drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

Breakup by Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Stores

Breakup by Region:
North America
United States
Asia Pacific
South Korea
United Kingdom
Latin America
Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited. Key Questions Answered in This Report:
How has the global alzheimer’s drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global alzheimer’s drugs market?
What are the key regional markets?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global alzheimer’s drugs market and who are the key players?
What is the degree of competition in the industry?